Related Experiment Video
Updated: Jul 3, 2026
10:02
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
Can neonatal myasthenia gravis be predicted?
Snjezana Gveric-Ahmetasevic1, Ana Colić, Vesna Elvedji-Gasparović
1NICU, Department of Perinatology, University Hospital for Obstetrics and Gynecology, Clinical Hospital Center Zagreb, University Medical School, Zagreb, Croatia. snjezana1@hi.t-com.hr
Journal of Perinatal Medicine
|August 7, 2008
Summary
Maternal myasthenia gravis (MG) duration and therapy do not predict neonatal myasthenia gravis (NMG) risk. High-risk pregnancies should deliver in specialized centers due to potential NMG severity.
Area of Science:
- Neurology
- Obstetrics
- Neonatology
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Neonatal myasthenia gravis (NMG) can occur in infants born to mothers with MG.
- Predicting NMG risk in newborns is crucial for appropriate perinatal care.
Purpose of the Study:
- To investigate the association between maternal MG characteristics and NMG occurrence.
- To determine if maternal illness duration or treatment influences NMG development.
- To identify factors predicting NMG in infants of affected mothers.
Main Methods:
- Prospective study of pregnant women with MG and their newborns over nine years.
- Comparison of 16 newborns with NMG and 33 healthy controls.
- Evaluation of maternal MG duration (<5, 5-10, >10 years) and therapy (none, mestinon, corticosteroids, combination).
Main Results:
- Maternal MG duration did not significantly predict NMG outcomes (P=0.159).
- Maternal therapy type was not associated with NMG development (P=0.578).
- No clear correlation found between maternal disease factors and neonatal outcomes.
Conclusions:
- Maternal myasthenia gravis duration and treatment do not correlate with NMG manifestation.
- These factors do not predict which pregnancies will result in an NMG-affected infant.
- High-risk pregnancies necessitate delivery in tertiary care centers due to potential NMG severity.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...